Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence

Journal of B.U.ON.

Volumn 17, Issue 4, 2012, Pages 735-739

  Stathopoulos, George P ^a   Papadimitriou, Ch ^b   Aravantinos, G ^c   Rigatos, S K ^d   Malamos, N ^d   Stathopoulos, J G ^a   Kaparelou, M ^a   Koutantos, J ^a   Andreadis, Ch ^e  

^a Errikos Dunant Hospital   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c Ag Anargyri Cancer Hospital   (Greece)

^d Marika Iliadi Hospital   (Greece)

^e THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Maintenance therapy; Ovarian cancer

Indexed keywords

ANTHRACYCLINE; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE;

EID: 84872425403     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fishman DA, Schwartz PE. Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol 1994; 6: 98-104.
2. Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 8-29.
3. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
4. Bookman MA, McGuire WP III, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-1902.
5. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
6. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds): Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, Philadelphia 2001, pp 1597-1632.
7. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004; 10: 7439-7449.
8. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284-289.
9. Gershenson DM, Mitchell MF, Atkinson N et al. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial cancer: "maintenance" therapy reconsidered. Gynecol Oncol 1992; 47: 7-13.
10. Cesano A, Lane SR, Poulin R, Ross G, Fiels SZ. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999; 15: 1233-1238.
11. Möbus V, Pfall PN, Volm T, Kreinberg R, Kanbitzschs J. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. Anticancer Res 2001; 21: 3551-3446.
12. Von Gruenigen VE, Karlen JR, Waggoner SE. A case of chronic paclitaxel administration in ovarian cancer. Gynecol Oncol 2003; 89: 532-535.
13. Kudelka AP, Tresukosol D, Edwards CL et al. Phase III study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-1557.
14. Creemers GJ, Bolis G, Gore M et al. Topotecan: an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J Clin Oncol 1996; 14: 3056-3061.
15. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193.
16. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as a first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 1062-1067.
17. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
18. Dizon DS, Hensley ML, Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application towards a dynamic disease state model of ovarian cancer. J Clin Oncol 2002; 20: 1238-1247.
19. Therasse P, Arbuck SG, Eisenhower EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
20. Gonzalez-Martin AJ. Medical treatment of epithelial ovarian cancer. Expert Rev Anticancer Ther 2004; 4: 1125-1143.
21. Salzberg M, Thürlimann B, Bonnfois H et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68: 293-298.
22. Partidge EE, Phillips JL, Menck HR. The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 1996; 78: 2236-2246.
23. Ozols RF, Markham M, Thigpen JT. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet 2002; 360: 505-515.
24. Freidlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pretreated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9: 1343-1345.
25. Allen DG, Heintz AP, Touw F W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995; 16: 349-356.
26. Cantu MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20: 1232-1237.